Anaphylaxis Treatment Market Report 2025

The anaphylaxis treatment market size has grown strongly in recent years. It will grow from $6.19 billion in 2024 to $6.61 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increasing incidence of allergic reactions, wider recognition of anaphylaxis, increased availability of epinephrine auto-injectors, public awareness and education, healthcare professional training.

The anaphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $8.72 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to innovation in biologic therapies, customized treatment approaches, global efforts on food safety, patient empowerment and advocacy, enhanced emergency medical services. Major trends in the forecast period include auto-injectors innovation, telemedicine for anaphylaxis management, improved allergen immunotherapy, biometric wearables for allergen detection, collaborations in allergy research.

The rising prevalence of food allergies is expected to drive the growth of the anaphylaxis treatment market. Food allergy refers to an immune response triggered by proteins in food. Anaphylaxis treatment is crucial in preventing the progression of life-threatening allergic reactions that affect the skin, mucosal surfaces, respiratory function, blood pressure, and vital organs. For instance, in January 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that in 2021, 31.8% of adults aged 18 and older experienced eczema, a seasonal allergy, or a food allergy. Among these, 25.7% had a seasonal allergy, 6.2% had a food allergy, and 7.3% had eczema. Additionally, in August 2024, the Food Standards Agency, a UK-based non-ministerial department, revealed that 296 valid case reports were submitted to the Registry between October 2021 and August 27, 2023. These reports likely reflect less than 5% of accidental reactions in the UK, with 213 (72%) attributed to food triggers and 208 (97.7%) occurring in individuals aged 18 or younger, with only 28 clinics and 11 Accident & Emergency (A&E) departments registered for access to the platform. Thus, the increasing prevalence of food allergies is driving the growth of the anaphylaxis treatment market.

The growth of the anaphylaxis treatment market is also expected to be driven by rising healthcare expenditure. Healthcare expenditure refers to the total spending on healthcare goods and services over a specific period, typically at the national level or within a healthcare system. Increased healthcare spending improves access to anaphylaxis treatment options, ensuring timely availability of life-saving medications, fostering research and development efforts, creating alternative treatment options, improving emergency response systems, and implementing preventive measures. For example, in September 2024, the Centers for Medicare and Medicaid Services (CMS), a US-based federal agency, reported that US healthcare expenditure grew by 4.1% in 2022, reaching $4.5 trillion, equivalent to $13,493 per person and representing 17.3% of the nation's gross domestic product. Therefore, the increase in healthcare expenditure is contributing to the growth of the anaphylaxis treatment market.

Advancements in product development mark a significant trend in the anaphylaxis treatment market. Major industry players are intensifying their product innovations to maintain a competitive edge. For example, in April 2022, Aquestive Therapeutics Inc., a US-based pharmaceutical firm, secured Fast Track designation from the Food and Drug Administration for AQST-109, an orally administered epinephrine product candidate designed for treating severe allergic responses, including anaphylaxis. This pioneering solution is a notable milestone, showing comparable clinical outcomes to autoinjectors such as EpiPen and Auvi-Q in managing allergic emergencies.

Companies at the forefront of the anaphylaxis treatment market are prioritizing innovative solutions such as the sulfite-free epinephrine injection to drive market growth. This injection, a crucial life-saving medication for severe allergic reactions, has witnessed advancements in its formulations. For instance, in March 2023, American Regent Inc., a leading US-based pharmaceutical company, launched a sulfite-free epinephrine injection USP. This product, suitable for subcutaneous, intramuscular, and intravenous administration, boasts a formulation devoid of sulfites or preservatives. Notably, it's recommended for adult patients experiencing hypotension due to septic shock to elevate mean arterial blood pressure.

In October 2023, the US-based biopharmaceutical company Amgen Inc. completed the acquisition of Horizon Therapeutics Plc for a substantial sum of $27.8 billion. This strategic move positions Amgen to expand its product portfolio, enabling the company to provide treatments for severe inflammatory, autoimmune, and rare disorders. The acquisition underscores Amgen's commitment to leveraging biotechnology to address the healthcare needs of patients facing life-threatening conditions. Horizon Therapeutics PLC, based in Ireland, is a biopharmaceutical company with a focus on developing innovative therapeutic solutions.

Major companies operating in the anaphylaxis treatment market include Merck & Co. Inc., Novartis International AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies, Sun Pharmaceutical Industries Ltd., Perrigo Co, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., ALK-Abelló A/S, Amphastar Pharmaceuticals Inc., Par Pharmaceutical Inc., Genentech Inc., Meridian Medical Technologies LLC, Aquestive Therapeutics Inc., Sandoz Inc., Adamis Pharmaceutical Corporation, Impax Laboratories LLC.

North America was the largest region in the anaphylaxis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaphylaxis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anaphylaxis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anaphylaxis treatment involves addressing life-threatening allergic reactions to allergens such as foods, insect stings, medications, and latex. Immediate administration of epinephrine is crucial to counteract the allergic response and stabilize the patient's condition. Effective management of anaphylaxis requires rapid medical intervention and comprehensive supportive care to alleviate potentially life-threatening symptoms.

Key treatments for anaphylaxis include epinephrine, antihistamines, steroids, beta-antagonists, and other supportive measures. Epinephrine, a synthetic or extracted form of adrenaline, is the primary and essential therapy for anaphylaxis. It must be administered promptly upon identifying the condition to prevent the onset of severe symptoms. These treatments are available in various forms such as tablets and capsules and are distributed through hospital pharmacies, retail pharmacies, and online platforms, addressing allergies such as food allergies, pollen allergies, dust mite allergies, and others.

The anaphylaxis treatment market research report is one of a series of new reports that provides anaphylaxis treatment market statistics, including anaphylaxis treatment industry global market size, regional shares, competitors with an anaphylaxis treatment market share, detailed anaphylaxis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the anaphylaxis treatment industry. This anaphylaxis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anaphylaxis treatment market consists of sales of bronchodilators, corticosteroids, and vasopressors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.